Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Correction to Merck to Buy OncoImmune Article

11/23/2020 | 08:23am EST

OncoImmune reported positive results from a late-stage study of a coronavirus therapeutic candidate. "Merck to Buy OncoImmune Amid Covid-19 Vaccine Development," at 6:59 a.m. ET incorrectly said that OncoImmune reported positive results from a late-stage study of a coronavirus vaccine candidate.

(END) Dow Jones Newswires

11-23-20 0822ET

All news about MERCK & CO., INC.
01/14Philips Partners with Merck to Develop Digital Systems for Fertility Treatmen..
MT
01/13Ligand Pharmaceuticals to Receive $1.5 Million Milestone Payment From Merck
MT
01/13MERCK : Confirms Agreement with UNICEF to Establish the World's First Global Ebo..
PU
01/12EISAI : To present data on lenvima monotherapy and in combination with keytruda ..
AQ
01/12MERCK : Gets FDA Priority Review of V114 Vaccine for Adults
DJ
01/12MERCK : Says FDA Accepts for Priority Review the Biologics License Application f..
MT
01/12MERCK : U.S. FDA Accepts for Priority Review the Biologics License Application f..
BU
01/11MERCK : to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference ..
AQ
01/08Merck Create Advisory Panel to Address Company-Wide Digital Ethics
MT
01/08MERCK : to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference ..
BU
More news
Financials (USD)
Sales 2020 48 200 M - -
Net income 2020 12 144 M - -
Net Debt 2020 15 159 M - -
P/E ratio 2020 17,6x
Yield 2020 2,94%
Capitalization 211 B 211 B -
EV / Sales 2020 4,69x
EV / Sales 2021 4,32x
Nbr of Employees 71 000
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 96,95 $
Last Close Price 83,38 $
Spread / Highest target 28,3%
Spread / Average Target 16,3%
Spread / Lowest Target 1,94%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.1.93%210 954
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
PFIZER INC.-0.30%203 993
ABBVIE INC.3.15%195 120